Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Next Previous
Search
Trial Profile

A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relmacabtagene-autoleucel (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Jun 2024 According to Results presented at the 25th Annual Congress of the European League Against Rheumatism, patients will be followed up further and more patients will be dosed with higher doses to observe long term safety and efficacy as well as to determine the potential target treatment dose.
    • 15 Jun 2024 Results (n=3; as of Dec 2023) reporting preliminary data presented at the 25th Annual Congress of the European League Against Rheumatism
    • 30 May 2024 According to a JW Therapeutics Media Release, as of April 8, 2024, a total of 12 patients enrolled and received the single infusion of relma-cel.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top